| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6de86cf6d28728b549dc2361d841b8ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2400-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-532
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2019-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10a723d102767bfab3f18f0a8198c5c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9eb2490b2e27ed7c0a1f9fbee9e893c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdfb856b23f5942caa996bbfc673a40e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eec419f75b1df0bbd0bb58299db98b09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25a8e8540323f86f2feeca166b62c29c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffec27a1a238491f1fc176758d9bfe9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cc052bfaab52951314c86f1de214525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d311b084155ad1392b83d3d2d0ddba1c |
| publicationDate |
2020-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2020060585-A |
| titleOfInvention |
Cell surface prostate cancer antigen for diagnostics |
| abstract |
PROBLEM TO BE SOLVED: To specify a biomarker in a biological sample that can be used for detection of prostate cancer. The present invention provides compositions and methods for detecting prostate cancer in a body fluid or tissue of a patient. Prostate cancer is detected by measuring the level of glypican-1 in a body fluid sample. In one embodiment, prostate cancer is detected by contacting a body fluid sample with an anti-glypican-1 antibody such as MIL-38. The present invention includes a kit for detecting prostate cancer in a body fluid sample, which comprises an anti-glypican-1 antibody and a glypican-1 standard. [Selection diagram] None |
| priorityDate |
2014-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |